Key Dates

Related Announcements

• October 9, 2020 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional). See Notice PA-20-272.

Issued by

Office of The Director, National Institutes of Health (OD)

National Eye Institute (NEI)

National Heart, Lung, and Blood Institute (NHLBI)

National Human Genome Research Institute (NHGRI)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute on Deafness and Other Communication Disorders (NIDCD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Environmental Health Sciences (NIEHS)

National Institute of Mental Health (NIMH)

National Institute of Neurological Disorders and Stroke (NINDS)

National Institute on Minority Health and Health Disparities (NIMHD)

National Library of Medicine (NLM)

Fogarty International Center (FIC)

National Center for Complementary and Integrative Health (NCCIH)

National Center for Advancing Translational Sciences (NCATS)

Office of Strategic Coordination (Common Fund)

National Cancer Institute (NCI)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of AIDS Research (OAR)

Office of Behavioral and Social Sciences Research (OBSSR)

Sexual and Gender Minority Research Office (SGMRO)

Office of Research on Women's Health (ORWH)

Office of Data Science Strategy (ODSS)

Tribal Health Research Office (THRO)

Purpose

 The NIH Office of Science Policy (OSP) within the Office of the Director (OD) announces the availability of administrative supplements to support:

1) research on bioethical issues to develop or support the development of an evidence base that may inform future policy directions, and/or

2) certain efforts to develop or augment bioethics research capacity. 

Background

Ethical considerations are intrinsic to the conduct of biomedical and health-related behavioral research and the translation of scientific and technological advances into practice. Research addressing bioethical issues can provide data to inform the conduct of biomedical, health-related, and behavioral science research and associated policies. Ethical questions and challenges are interlinked with many of NIH’s areas of scientific priority, such as responding to public health needs (e.g., lasting effects of the COVID-19 pandemic, the opioid crisis) and emerging scientific opportunities (e.g., new data sharing approaches, mainstream use of artificial intelligence). The investment in and the integration of bioethics-related research and policy demonstrate NIH’s commitment to advancing ethical research which can facilitate public participation and trust in the research enterprise.

Specific Areas of Interest

The OD is particularly interested in applications that identify, analyze, and/or address bioethical issues. The proposed bioethics question, issue, or topic must be clearly articulated and applicants must explain how proposed bioethics activities are related to the scope of the specific aims of the parent grant. Examples of such projects include, but are not limited to:

Collection, Use, and/or Sharing of Real-World Data (e.g., data collected from clinical care settings)

• Designing and evaluating tools or approaches to aid individual, family, and community decision-making and education about collection, use, and/or sharing of real-world data
• Studies that examine understanding of ethical issues related to collection, use, and/or sharing of real-world data among researchers and/or examine issues related to sharing and disclosure of information about the use of that data for biomedical and/or health-related behavioral research
• Analyzing ethical, legal, and policy issues raised by research use of electronic health record data, digital health data, and other data collected in clinical care or research settings, (e.g., privacy, data governance, consent)
• Studies that examine how bioethical principles can aid design of electronic health records
• Studies that examine patient preferences related to use of their personal health data
• Evaluations of practices related to using digital health technologies in research, including issues related to data privacy and data security, consent, transparency, access, and equity
• Studies that examine ethical issues related to the use of digital health technologies and/or digital health data for biomedical and/or health-related behavioral research
• Considerations for using real-world data to generate knowledge for biomedical and/or health-related behavioral research

Patient, Community, and Public Engagement

• Studies on strategies or methods for effectively engaging patients (and/or patient caregivers, allies, or others who can represent a patient’s lived experience) and communities as partners in research, including integrating patient and community voices in clinical research design and longer-term engagement with the scientific enterprise
• Engaging with patients and communities about the use of novel data from outside of the traditional healthcare system (e.g., from wearables, apps, and social media), analysis of health data using generative artificial intelligence and machine learning (AI/ML) models and algorithms, or data linkage and aggregation of disparate datasets from multiple sources
• Assessments of community attitudes toward biosafety, biocontainment, and biosecurity policies, practices, and risk mitigation techniques in biomedical research

Return of Research Results

• Assessments of participant preferences regarding the return of aggregate and/or individual research results, frameworks for respecting individual participant preferences for receiving (or not receiving) research results, and methods for responsibly returning various types of research results to participants across various clinical fields, including results from clinical tests, environmental health measurements, and non-genomic data
• Research to help understand how people interpret and act upon receiving aggregate and individual research results

Biospecimen and Data Sharing

• Empirical assessments of the value of biospecimen and data sharing
• Implications for participant consent and privacy when conducting data linkage, including linking genomic with non-genomic data or controlled-access data with publicly available data
• Research to develop or refine existing methods, tools, or technologies (e.g., de-identification) to facilitate appropriate biospecimen and data sharing while protecting research participant privacy, including for datasets that contain indirect identifiers and sensitive data
• Research to elucidate ethical issues (e.g., potential re-identifiability) raised by the sharing of multi-omics data, including proteomics, metabolomics, and microbiomics, as well as possible risk mitigation options
• Practices, tools, technologies, and/or perspectives on obtaining informed consent for de-identified biospecimen and data sharing in settings that may not typically involve research consent (e.g., social media, clinical or public health settings where data is de-identified)
• Practices, tools, and technologies for communicating the status of consent as well as data use limitations to downstream users of data
• Research on processes that institutions undertake to assess the risks of sharing de-identified biospecimens and data, evaluation of those processes, and how to optimize those processes for improved biospecimen and data sharing and participant protection

New and Emerging Technology Development and Use

• Research on the ethical issues raised by gene editing, organoids (e.g., neural organoids), AI/ML, neural implants and invasive or non-invasive modulation, consumer-generated data, synthetic biology, gene drives, and/or xenotransplantation
• Horizon scanning to anticipate ethical, legal, and social implications of emerging technology advances and develop resources to enable biosafety and biosecurity risk assessments and risk mitigation tools
• Research on the ethical issues and broader impacts (e.g., health disparities) stemming from the lack of standards for both new and emerging technologies and analytical platforms, endpoint measures, characterization of biological materials used in models, and reporting of results
• Research on the ethical issues raised by attempts to maximize translatability and minimize bias in the application of new and emerging technologies
• Research on the ethics and norms surrounding advances in biotechnology, biomanufacturing, and expanded applications through convergence of biology with other technologies
• Tools and best practices to enhance the culture of responsible biosafety and biosecurity in biotechnology and biomanufacturing innovation
• Capacity building needed for ethical and equitable development and use of these technologies

Advancing Diversity, Equity, and Inclusion in Innovation and Research

• Research on approaches that various institutions are taking to advance diversity and inclusion in innovation
• Research on approaches that promote participation of historically excluded groups in innovation and entrepreneurship
• Research on approaches to reduce barriers to participation in research that might offer direct benefit to individuals from a vulnerable group and/or individuals with disabilities

Population Descriptors in Research

• Designing and evaluating tools or approaches to aid researchers and the media in communicating concepts of genetic similarity to researchers and the public
• Analyzing ethical, legal, and policy issues on whether and how to use population descriptors using legacy data
• Implementing and analyzing approaches to incorporate community engagement to inform use of populations descriptors in research
• Analyzing ethical, legal, economic, or social issues raised by requiring researchers to report their rationale regarding the use of population descriptors in research
• Studies that examine the understanding of ethical, regulatory, policy, and societal issues related to inclusion enrollment reporting and the use of population descriptors in research study design

Projects to Develop or Augment Bioethics Research Capacity in Supported Areas

• Projects that directly strengthen and/or sustain the field of bioethics such as the development of educational content (e.g., curricula, practicum experiences for trainees, publicly accessible web-based modules) and new or innovative resources, tools, and/or strategies addressing bioethical challenges

Research on Topics that Can Develop or Support the Development of an Evidence Base that May Inform Future Policy Directions.

Policies of interest include current NIH-issued policies or potential future policy directions, other federal policies, laws, and regulations, as well as policies governing the practice of research, medicine, or public health. Issues of interest should fall within the scope of research supported by NIH but may be beyond the focus of any one Institute or Center. Overarching areas of interest may include but are not limited to:

• Big data and data science analytics, integration of data for research (e.g., clinical, research, environment, social media, participant/patient provided, and/or other data types), biases in datasets and algorithms, research using electronic health record data, and ethical implications for the use of non-traditional data (e.g., social media information, consumer data) for research purposes
• Precision and personalized medicine
• Learning Healthcare System (i.e., a system designed to generate and apply the best evidence for the collaborative healthcare choices of each patient and provider; to drive the process of discovery as a natural outgrowth of patient care; and to ensure innovation, quality, safety, and value in health care), interface of clinical research and clinical care, and pragmatic trials
• Issues related to public health research, including emergency, disaster, and pandemic research
• Individual or community health, treatment, and/or research disparities; accessing and sharing benefits of research; post-study obligations; patient access to drugs and medical services
• Issues related to the inclusion of populations underrepresented in biomedical and/or health-related behavioral research, including sexual and gender minorities, people from racial and ethnic minority groups, people living with disabilities, non-U.S. born persons, people experiencing poverty, children, older adults, formerly or currently incarcerated individuals, and other marginalized communities
• Issues related to the inclusion of Tribal members and American Indian/Alaska Native populations in biomedical and/or health-related behavioral research
• Research involving individuals who are pregnant/lactating
• Research involving individuals potentially at higher risk for undue influence, including for pediatric and palliative care research
• Issues related to aging research
• Issues related to health disparities and health inequities, including effects of structural racism and ableism on the biomedical and health-related behavioral research enterprise
• Current and emerging regulatory and policy environments, including NIH environments
• Bioethical issues pertaining to how drug policies can influence health-related behaviors and patterns and trends in drug use, perceptions, and attitudes
• Innovative study design, conduct, management, and oversight, including methods for obtaining and documenting informed consent; virtual or decentralized clinical trials; and other remote or passive sensing, monitoring, or assessment methods
• International research, including research in resource-constrained settings, transnational research, and research in low- and middle- income countries
• Research on stigmatized conditions
• Historical analyses of bioethics issues
• Novel approaches for developing, enhancing, and measuring effectiveness of bioethics infrastructure and training
• New means for assessing and enhancing the scientific workforce, including policies promoting scientific workforce diversity and inclusion and promoting a safe and inclusive research environment (see Advancing Antiracism, Diversity, Equity, and Inclusion in STEMM Organizations: Beyond Broadening Participation |The National Academies Press)
• Issues related to collecting, analyzing, and applying data related to social determinants of health

 Areas that will NOT be supported include IRB management, funding for employees to meet human subjects research competency requirements, and training slots.

ICO Areas of Interest

In addition to overarching areas of interest, individual NIH Institutes, Centers, and Offices (ICOs) have indicated the following specific areas of research interest:

FIC

The Fogarty International Center (FIC) is interested in research and sustainable capacity building activities on ethical issues relevant to low- and middle-income countries, in particular studies conducted by investigators in these countries.

NCATS

The National Center for Advancing Translational Sciences (NCATS) is interested in research on ethical issues that cross disease domains and span the translational research spectrum. NCATS encourages collaboration between translational researchers and bioethics researchers on projects addressing ethical challenges in moving discoveries from laboratory, clinic, and community into interventions that improve health.

NCCIH

The National Center for Complementary and Integrative Health (NCCIH) is interested in bioethics applications that address topics relevant to its mission and research priorities as provided in its Strategic Plan. For information, please see: https://nccih.nih.gov/about/plans.

NCI

The National Cancer Institute (NCI) is interested in bioethics issues relevant to cancer research and healthcare delivery, such as issues raised in cancer clinical trials, cohort studies, cancer prevention studies, cancer centers, cancer surveillance, prospective biobanking, studies using previously collected samples/tissues, or studies re-using previously collected data. Bioethical issues of interest include, but are not limited to:

• Issues raised by novel cancer therapies or diagnostic technologies
• Issues raised by use of genetic testing for cancer screening or prevention studies
• Issues raised by use of ancestry markers vs. ethnicity/race in cancer research, care, or prevention
• Issues raised by use of AI/ML in cancer research or care
• Issues raised by use of digital health technology (e.g., telehealth, wearables, implantable sensors, mobile apps in cancer research), including disparities in access to technology, inclusivity and usability of technology, and data ownership; see also the issues highlighted above on the impact of digital health and/or real-world data issues
• Issues raised by use of social media as data sources or cancer control intervention platforms, including consent, privacy, data access, and algorithmic issues related to social media data
• Privacy, confidentiality, and governance of data and ethical re-use of data, including data originally collected in a broad range of settings
• Innovative models for data governance
• Community, patient, or participant engagement
• Return of research results
• Participant or patient perception and comprehension
• Effective communication and cancer prevention
• Patient-centered communication, including patient-provider and to/within families
• Prognosis and goals of care communication
• Innovative methods and technologies for recruitment, retention, and ongoing engagement of participants who are underserved and/or vulnerable, hard to reach, or otherwise underrepresented in research
• Access to care for populations with cancer disparities
• Effective approaches to increase transparency in research
• Issues related to cancer research on individuals whose age, illness, or cognitive impairment do not allow them to provide informed consent or independently complete self-report measures
• Issues raised by advance care planning
• Addressing challenges of conducting cancer-related trials on cannabinoids due to variations in state laws and access

NCI encourages investigators to contact the parent grant program officer to address any budgetary issues prior to submitting a supplement application.

NEI

The National Eye Institute (NEI) is interested in bioethics applications that address topics relevant to research on mechanisms of visual function, prevention, and treatment of vision diseases, and improving quality of life through expanding opportunities for people who are blind or have low vision. For more information about NEI’s mission and research priorities, please see its Strategic Plan:  https://www.nei.nih.gov/about/strategic-planning

NHGRI

The National Human Genome Research Institute (NHGRI) is interested in research related to the ethical, legal, regulatory, policy, economic, cultural, and societal issues raised by the advancement and use of genomics and the interactions between genomics and the physical and social environment. These issues may relate to:

• The design and conduct of research in genetics and genomics
• The translation of genetic and genomic research into clinical medicine and health care
• The interplay among a broad array of interested individuals and entities in the field of genomics
• The value and meaning of genomics for the broader public

Examples of possible topics of interest are available on the ELSI Research Areas and Sample Topics website: https://www.genome.gov/Funded-Programs-Projects/ELSI-Research-Program/research-areas.

NHLBI

The National Heart, Lung, and Blood Institute (NHLBI) is interested in research on bioethics issues relevant to its Strategic Vision (https://www.nhlbi.nih.gov/about/strategic-vision), and its focus on heart, lung, blood, and sleep conditions. Specific examples include, but are not limited to:

• Addressing bias and health equity in heart, lung, blood, and sleep research
• The return of research results (e.g., genomic, omic, environmental) with context to participants and communities, such as environmental toxins that may impact community health, the handoff between research and clinical care, and providing genetic counseling at large scales
• Bioethical questions related to gene editing, such as examining the ethical issues of generating chimeric animals for human organ transplantation, discerning the difference between genetic therapy and genetic enhancement, consideration of the effect of patenting gene editing technologies, and consideration of the high cost of gene therapy and its effect on accessibility
• Bioethical questions related to novel ways of addressing the shortage of organs for heart and lung transplantation. Please refer to our workshop summary: https://www.nhlbi.nih.gov/events/2023/heart-and-lung-transplantation-science-and-ethics-dcdd-and-xenotransplants-hybrid
• Bioethical questions raised by the COVID-19 pandemic, such as ethical rationing of/equitable access to mechanical ventilators
• Issues related to clinical trials, including adaptive clinical trial designs, usual care arms, or other novel designs
• Bioethical questions related to implementation science research
• Waivers of informed consent, exceptions from informed consent, or obtaining consent from surrogates
• Ethics of cardiopulmonary support, including end-of-life care and support/device withdrawal
• Novel and emerging technologies, such as machine learning bias or algorithm overreach and physician autonomy
• Privacy and confidentiality, especially in large datasets, such as AI applied to imaging data or concerns that may arise from multi-omics profiles
• The impact of NIH policy changes, such as updates to the management of genomic summary results
• Issues related to working with understudied or vulnerable populations or creating culturally appropriate messaging, especially with regards to American Indian/Alaska Native populations and Tribal Sovereignty

Investigators are encouraged to contact NHLBI staff to discuss their ideas.

NIA

The National Institute on Aging (NIA) is interested in applications that address topics relevant to its core mission. For more information, please see: https://www.nia.nih.gov/about/mission.

NIAAA

The mission of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) is to generate and disseminate fundamental knowledge about the adverse effects of alcohol on health and well-being, and apply that knowledge to improve diagnosis, prevention, and treatment of alcohol-related problems, including alcohol use disorder (AUD), across the lifespan. NIAAA is interested in bioethics applications that address topics relevant to its mission, research objectives, and cross-cutting research areas as outlined in its Strategic Plan at: https://www.niaaa.nih.gov/strategic-plan.

Examples of bioethical issues of interest include but are not limited to:

• Impact of stigma on recruitment and retention of clinical trial participants with alcohol misuse, AUD, and co-occurring disorders, including individuals from underserved, high-risk, and hard to reach populations
• Pharmacotherapy research involving pregnant people and adolescents
• Issues related to the inclusion of females, sexual and gender minorities, and other populations underrepresented in alcohol research
• Health provider attitudes towards patients with AUD in need of liver transplantation

Investigators are strongly encouraged to contact NIAAA staff to discuss their ideas.

NIAID

The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting supplemental projects that focus on ethical, legal, and social implications (ELSI) relevant to domestic and international collaborative research on HIV/AIDS or its co-morbidities (e.g., Mpox, TB, malaria, hepatitis, sexually transmitted infections); other infectious diseases including those transmitted by vectors, immunologic and allergic diseases, and/or organ transplantation; ethics of clinical trials and implementation science; and other ELSI issues relevant to NIAID's scientific mission. Applications may include conceptual work in bioethics, or empirical work gathering and analyzing data relevant to ethical issues in research, or a combination of the two. For empirical projects, data collection may include quantitative or qualitative methods, or both. Although not intended to be an exhaustive list, of particular interest to the respective divisions of NIAID are projects on:

• Research involving adolescents and young adults, including autonomy and informed consent
• Issues at the intersections of public health surveillance, care delivery, and research 
• Improving the inclusion and/or enhanced engagement of key populations, including pregnant people, in research on HIV prevention, treatment, cure; HIV-related comorbidities and co-infections including those transmitted via sexual contact; improving dissemination, communication of results, mitigating barriers to research participation
• Improving the representation of key populations in research on other infectious diseases, organ transplantation, and immune-mediated diseases; improving dissemination, communication of results, and mitigating barriers to research participation
• Community engagement and attitudes concerning organ transplantation, including xenotransplants; novel vector control measures, vaccines, treatment, prevention, and other public health mitigation strategies for a specific infectious disease or co-occurring infectious diseases
• Bioethical issues and community acceptance of controlled human infection trials
• Informing study designs for safety and efficacy evaluations of interventions; best practices for development and uptake of future treatment and/or prevention strategies
• Methods for securing highly sensitive human data and genetic data; risks from data breaches and reidentification; effective tools for anonymizing sensitive data; interested parties’ attitudes toward data sharing methods and policies
• Bioethical issues associated with genome editing techniques to correct heritable traits and genetic disorders within NIAID’s mission

NIAMS

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in bioethics applications that address topics of relevance to the NIAMS mission and research priorities as provided in its Strategic Plan: https://www.niams.nih.gov/sites/default/files/pdf/NIAMS-StrategicPlan-2020-2024-v1.pdf.

NIBIB

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is interested in bioethics research relevant to its mission to support the development of innovative technologies in bioimaging and bioengineering. Areas of interest to NIBIB include, but are not limited to:

• Ethical frameworks/considerations associated with all stages of the design, testing, and/or implementation of the biomedical technology development continuum from initial design stages through their application in human health (i.e., bench to bedside) as they relate to patient safety, data privacy, accessibility, and patient/public engagement
• Ethics research into the social impact and implications of new and emerging biotechnologies and methodologies, such as AI/ML, data science, nanotechnologies, synthetic biology, and living materials
• Ethical considerations and best practices for using AI/ML for research and clinical use, such as use of ethically sourced training data, data security and privacy, data integrity, strategies to minimize algorithm bias, strategies to improve transparency, accountability and explainability of these algorithms, and ethical considerations in patient privacy and confidentiality
• Ethical issues associated with digital health and wearable/implantable technologies or health/mHealth and Point-of-Care (POC) technologies, such as device bias, return of research results, re-identifiability of real-world data, and strategies to mitigate these risks
• Ethical issues associated with the use of biomedical imaging technologies, such as patient accessibility and affordability issues, risks associated with re-identifiability of publicly available raw and processed imaging data, informed consent, and data privacy and security
• Ethical considerations in biomaterials and tissue engineering for regenerative purposes, including patient-derived iPSC/organoid systems, 3D bioprinting, and biohybrid devices. These include, but are not limited to, considerations for the use of human-derived materials for research purposes, risk and safety of engineered tissues, clinical translation of such technologies, and ownership issues that arise from use of engineered tissues for transplantation in the clinic
• Bioethical issues related to the development and translation of bionic and robotic devices, which include both invasive and non-invasive technologies used by and for humans to replace, regulate, or otherwise assist human function
• Ethical issues as they relate to health disparities, bias, and inclusion in biomedical research 

Investigators are strongly encouraged to contact the NIBIB Scientific/Research Contact listed below to discuss their ideas.

NICHD

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is interested in bioethical issues relevant to research involving infants, children, and adolescents; pregnant and lactating people; and people with physical, intellectual, and/or developmental disabilities. Areas of particular interest include:

• Research in the fields of developmental biology, reproductive health, pediatrics, population health, prenatal and newborn screening, disabilities, and medical rehabilitation
• Research that addresses health disparities and improves prevention efforts among the populations served by NICHD
• Studies that examine facilitators and barriers to inclusion of NICHD’s populations of interest in biomedical research, including ableism, targeted recruitment approaches, and assent
• Areas identified as high-priority research areas to the institute are of particular interest

See https://www.nichd.nih.gov/grants-contracts/research-areas/priorities for the current research priorities for the institute and https://www.nichd.nih.gov/about/org/strategicplan regarding future themes for the institute.

NIDA

The mission of the National Institute on Drug Abuse (NIDA) is to advance the science of drug use and addiction and to apply that knowledge to improve individual and public health through:

• Strategically supporting and conducting basic, clinical, and epidemiological research on drug use, its consequences, and the underlying neurobiological, behavioral, and social mechanisms involved
• Ensuring the effective translation, implementation, and dissemination of scientific research findings to improve the prevention and treatment of substance use disorders (SUDs), reduce the harms associated with drug use, guide policies, enhance public awareness of addiction as a chronic but treatable medical illness, and reduce stigma

NIDA’s research advances fundamental knowledge and provides scientific evidence to inform individual and public health, including the policies and practices of other federal agencies; state and local health, education, and human services; and the legal system.

NIDA is interested in bioethical issues relevant to research involving all individuals, with particular attention to individuals who have, or are at risk of developing, SUDs with particular emphasis on vulnerable populations, including children, adolescents, pregnant people, and those with mental illnesses. Areas of particular interest in the context of this Bioethics NOSI include:

• Identifying and developing approaches to reduce stigma
• Understanding sex, sexual orientation, and gender differences
• Identifying and developing approaches to reduce health disparities
• Understanding interactions between substance use, HIV, and other comorbidities
• Leveraging data science and analytics to understand real-world complexity
• Ethical implications of data collection and sharing, including the potential for deductive disclosure and the consequences of publishing certain results for vulnerable populations
• Education about and implementation of standard procedures to mitigate the risk of disclosure for participants
• Ensuring responsible use of data related to substance use by considering socioenvironmental contexts known to introduce inequities, such as family income and education, employment, housing, neighborhood- level characteristics, and exposure to violence; and informing data analysis and interpretation through community-partnered research
• Developing personalized interventions informed by people with lived experience

NIDCD

The National Institute on Deafness and Other Communications Disorders (NIDCD) is interested in applications that address topics in the areas of hearing, balance, taste, smell, voice, speech, and language. For more information, please see: https://www.nidcd.nih.gov/about/strategic-plans.

NIDCR

The mission of the National Institute of Dental and Craniofacial Research (NIDCR) is to advance fundamental knowledge about dental, oral, and craniofacial (DOC) health and disease and translate these findings into prevention, early detection, and treatment strategies that improve overall health for all individuals and communities across the lifespan. NIDCR is interested in applications that advance the bioethics evidence base and/or support bioethics research capacity building that are within the scope of the 2021-2026 Strategic Plan (see: https://www.nidcr.nih.gov/about-us/strategic-plan). Specific areas of interest to NIDCR include, but are not limited to:

• Management of incidental findings about overall health from genetic and genomic studies that are focused on DOC phenotypes using research, health, and clinical data
• Approaches to mitigate privacy and confidentiality issues related to the public dissemination and reuse of research, clinical, and health data, including but not limited to facial images, audio and video data, multi-omics data, and associated metadata
• Assessment and management of risks, including but not limited to data re-identification or de-anonymization, resultant from the reuse of genomic and genetic data in combination with other sensitive or potentially identifiable DOC-relevant data types (e.g., facial imaging, vocal recordings and other biometrics, clinical diagnoses, and dental and health records)
• Approaches to identify and mitigate ethical dilemmas in biomedical research and oral healthcare AI, including but not limited to the biases in data input, modeling, and output, and the transparency and accountability of AI tools
• Implications of disease screening or treatment approaches where risk calculations are especially relevant (e.g., applying regenerative medicine technologies to treating non-life-threatening DOC diseases and conditions, routine screening for health conditions in the dental setting)
• Ethical and societal implications of applying precision medicine approaches to diagnosis, treatment, or management of DOC diseases and conditions

NIDDK

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is interested in applications that address topics relevant to its core mission.

For more information, please see: NIDDK Strategic Plan for Research - NIDDK (nih.gov).

NIEHS

The mission of the National Institute of Environmental Health Sciences (NIEHS) is to discover how the environment affects people in order to promote healthier lives. NIEHS is interested in applications that advance the bioethics evidence base and/or support bioethics research capacity building and are within the scope of its 2018-2023 Strategic Plan (https://www.niehs.nih.gov/about/strategicplan/index.cfm). Specific areas of interest to NIEHS include, but are not limited to:

Bioethics Evidence Base:

• Bioethical issues related to precision environmental health
• Bioethical issues related to community engaged/citizen science environmental health research
• Return of environmental health research results to participants/communities and/or building capacity to support the return of environmental health research results
• Bioethical issues related to the inclusion of populations underrepresented in environmental health research
• Bioethics of conducting environmental health disparities and environmental justice research in U.S. and low- and middle-income country settings
• Research on the bioethical issues associated with environmental health prevention and intervention strategies
• Bioethical issues focused on the impacts of climate change and climate change related disasters on health

Bioethics Research Capacity Building:

• Bioethics capacity building projects that support/enhance scientific workforce diversity in the environmental health sciences
• Capacity building projects to develop curricula/educational content for researchers and community members focused on environmental health bioethical issues

NIMH

The National Institute of Mental Health (NIMH) is interested in bioethics applications that address a range of issues for individuals and communities relevant to its core mission, and the subjects and disorders for which it serves as a primary lead at NIH. Such areas include, but are not limited to:

• Approaches that address changes in consent capacity among vulnerable research populations (e.g., children, cognitively impaired elders, actively psychotic patients)
• Studies that address the ethical issues associated with the use of AI/ML in psychiatric research or for use in a predictive/diagnostic manner
• Ethical considerations due to the use of digital health technology in psychiatric research
• Issues raised by use of social media as data sources or intervention platforms, including consent, privacy, and algorithmic issues related to social media data
• Development of novel approaches for addressing ethical issues associated with the use of brain neuromodulation technologies
• Developing best practices and guidelines for sharing with patients results from psychiatric research
• Studies examining the bioethical issues related to suicide research in younger children, including developmentally appropriate measures of suicidal intent, safe approaches to assessing suicide risk in young children, and developmentally appropriate interventions that mitigate risk for children endorsing suicidal thoughts or behaviors
• Evaluation of technologies for identifying suicide risk and approaches for monitoring and addressing states 

For further information about Institute priorities, please see: https://www.nimh.nih.gov/about/strategic-planning- reports/index.shtml.

NIMHD

The National Institute on Minority Health and Health Disparities (NIMHD) is interested in supporting research projects on the ethical, legal, and social implications of research participation and/or health care for NIH-designated U.S. health disparity populations which currently include Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and Pacific Islanders, Middle Eastern/North Africans, socioeconomically disadvantaged populations, underserved rural populations, sexual and gender minorities, and individuals with disabilities.  Projects focused on rural populations, SGM groups, and people with disabilities are encouraged to examine intersections with race and/or ethnicity, and/or socioeconomic status.

Areas of interest to NIMHD include, but are not limited to:

• Studies that seek to understand or address cultural preferences
• Studies that enhance the support of duties and responsibility to communities, without negatively impacting community or perpetuating negative stereotypes
• Values and norms to ensure ethical and equitable conduct of research and delivery of health care for populations and communities
• Ethical integration of social and biomedical sciences (e.g., social epigenomics and incorporation of social determinants into the health care system)
• Mitigating stigmatization, group harms, and unintended social implications of research
• Ethical considerations on screening for social needs and social determinants of health, particularly within healthcare settings
• Detecting and mitigating algorithmic biases for treatment eligibility, planning, and population health
• Studies that elucidate mechanisms and system processes that ensure full, informed protection in research
• Addressing digital health equity, particularly in implementation at the community and health system levels
• Addressing data sovereignty and data sharing with American Indians/Alaska Natives populations

NINDS

The National Institute of Neurological Disorders and Stroke (NINDS) is interested in research on neuroethical questions relevant to its mission to seek fundamental knowledge about the brain and nervous system and to use that knowledge to improve neurological health for all people. In addition to the general areas of interest listed above, areas of interest specific to NINDS include, but are not limited to, the ethical implications of:

• Aspects of neuroscience research with human participants, such as differing views of interested parties on trial design, return of research results to participants, informed consent-related issues (including but not limited to waivers of informed consent or exceptions from informed consent), or therapeutic misconception, including for rare diseases
• Issues related to human donors of biological materials, including, but not limited to, research with brain organoids or ex vivo human brain tissue
• Collecting and sharing human brain data, such as de-identification, privacy, and re-use practices
• The development and use of neuromodulation and neuroimaging technologies
• Predictive/diagnostic research related to brain disorders
• Advances in neural recording and/or neuromodulation specifically for use in children and people with a limited ability to consent for themselves
• Ensuring novel data sharing tools such as digital health technologies and electronic health records are inclusive of populations that experience health disparities with neurological disorders and stroke
• Designing and evaluating culturally appropriate tools or approaches to aid individual, family, and community decision-making and education about use of digital health technologies and/or real-world data, specifically for populations that experience neurological health and healthcare disparities
• Potential neurological health and healthcare disparities or inequities created by AI/ML
• Ethical consideration and best practice guidelines for community-engaged research (including bidirectional communication and input) with populations defined by NIH as experiencing health disparities and populations underrepresented in science, technology, engineering, and medicine (STEM)

Consistent with the description of capacity building efforts above, NINDS also is interested in capacity building efforts, including the development of educational content and new or innovative resources, tools, and/or strategies addressing neuroethical challenges relevant to the NINDS mission.

NINDS, as part of NIH, strives for rigor and transparency in all research it funds. For this reason, NINDS explicitly emphasizes NIH application instructions related to rigor and transparency (https://grants.nih.gov/policy/reproducibility/guidance.htm) and provides additional guidance to the scientific community (https://www.ninds.nih.gov/Funding/grant_policy).

Additional information about the NINDS mission may be found here: https://www.ninds.nih.gov/About- NINDS/Who-We-Are/Mission. Note that applications must consider neuroethical questions and be within the general scope of the parent award. Also, NINDS will not consider supplement applications that propose new basic research activities or research with vertebrate animals.

NLM

The National Library of Medicine (NLM) supports research that incorporates innovative biomedical informatics and data science approaches that harness the digital healthcare ecosystem and have the potential to reduce bias while improving personal health, access to care, continuity of care, and/or health outcomes. NLM’s vision is to unleash the potential of data and information to accelerate and transform discovery and improve health and health care. This important task understands that the use of data science and biomedical informatics methods, especially in health disparity populations, ethical principles of justice, and respect must be maintained using health-related data. For more information about NLM, please see the Strategic Plan: https://www.nlm.nih.gov/pubs/plan/lrp17/NLM_StrategicReport2017_2027.pdf.

NLM’s interests include, but are not limited to, areas of science that address:

• Research in algorithmic fairness in healthcare
• Issues related to ethical approaches to public health data
• Identification of data science and biomedical informatics approaches to translational science, including genomic approaches to health-related issues in health disparity populations
• AI/ML approaches to clinical and non-clinical data and analytics

OSC

The Office of Strategic Coordination (OSC) oversees the Common Fund, a funding entity within the NIH that supports bold scientific programs that catalyze discovery across all biomedical and behavioral research.

Applicants must hold an award from a Common Fund program and meet the Notice requirements. Certain Common Fund programs may have specific areas of interest for this Notice. Interested applicants are strongly encouraged to reach out to the listed OSC contact for further guidance.

OAR

The Office of AIDS Research (OAR) is part of the NIH Office of the Director and works in partnership with the NIH Institutes, Centers, and Offices (ICOs) in its coordination of the NIH HIV Research Program and to ensure that HIV/AIDS research is aligned with the NIH Strategic Plan for HIV and HIV-Related Research.

OAR does not award grants but co-funds HIV-related applications and research projects that have received an award from some of the participating ICOs listed in the announcement. Projects must align with at least one of the strategic goals and objectives outlined in the NIH Strategic Plan for HIV and HIV-Related Research. Please contact the relevant ICO Scientific/Research Contact(s) listed with any questions regarding ICO research priorities and funding.

ODSS

The Office of Data Science Strategy (ODSS) is interested in stimulating research to identify, analyze, and understand relevant ethical issues and their implications in data science related to the F.A.I.R. (Findable, Accessible, Interoperable, and Reusable) and C.A.R.E. (Collective Benefit, Authority to Control, Responsibility, and Ethics) principles, data ecosystems, and data access and sharing, or policy development and/or implementation of data security and data privacy in human subject’s research with regards to research ethics and integrity. For example, supporting projects that address 1) understanding ethical issues in broad knowledge domains to ensure ethical, meaningful, interpretable, and scalable utility of data from individuals and communities in individual, community, and population-level health and/or biomedical discovery, 2) enabling the expansion of diversity, equity, inclusion, and accessibility to enhance the scientific workforce for responsible data utility, access, and sharing, 3) exploring and implementing guardrails for novel use of technologies including new technologies in biomedical research, etc.

ORWH

The Office of Research on Women’s Health (ORWH) focuses on research that is relevant to the health of women, the inclusion of women in clinical studies, and the advancement of women in biomedical careers. ORWH is interested in research on bioethics issues that intersect with the goals, objectives, and guiding principles of the NIH-Wide Strategic Plan for Research on the Health of Women 2024-2028 (https://orwh.od.nih.gov/about/trans-nih-strategic-plan-womens-health-research). Specific examples include, but are not limited to:

• Ethical, legal, and social implications of sex and/or gender in research across the lifespan including ethical considerations of sex, gender, and intersectionality in basic, translational, clinical, and implementation science research
• Inclusion of an intersectional perspective in research involving women who are underrepresented, understudied, and underreported (U3) in biomedical research (e.g., women of underrepresented racial and ethnic communities; in economically disadvantaged groups; with physical, mental/intellectual, or sensory disabilities; who reside in underserved rural and urban areas; who are pregnant and lactating; and of sexual and gender minority groups) and the implications of implicit and explicit bias (e.g., racial, ethnic, sex, and/or gender) on the inclusion or exclusion of women from U3 populations in research
• Ethical issues governing the retainment and advancement of women in biomedical careers (e.g., power dynamics and/or differentials, gender harassment, hiring, promotion, and tenure) and issues related to women in STEAM disciplines or participating in team science and conducting interdisciplinary and/or trans-disciplinary research
• Bioethical issues derived from data generated in research and development (R&D) of drugs, medical devices, diagnostics, and emerging technologies, and health screenings (e.g., mammograms, Pap-smears, newborn screening, EKG) with particular interest in COVID-19 implications on the health of women
• Societal implications, such as stigma based on gender dimensions, related to sex and/or gender bias or considerations in the development and/or use of novel and emerging technologies (e.g., AI/ML, multi-accuracy auditing, digital/mobile health, social media tools)
• Neuroethics and ethics related to sex, gender, and intersectional (i.e., age, race/ethnicity) considerations in genomic and other basic and applied research including precision health
• Ethical and social issues raised in provider-patient interactions/relationships and family caregiving related to its impact on women’s health and well-being. This could include evaluation of sex and/or gender concordance or discordance between health care providers and patients.

Intersectional approaches are encouraged

SGMRO

The SGMRO develops and coordinates health- and research-related activities for sexual and gender minority (SGM; defined for NIH research in NOT-OD-19-139) populations independently and in conjunction with the NIH institutes, centers, and offices and serves as a liaison with the research community to ensure SGM populations are considered and represented in relevant activities across the agency. The SGMRO does not have grant-making authority or administer grants. The office can only support grants approved for funding after review by one of the institutes or centers (ICs) participating in this announcement and after a co-funding request is initiated through the IC. Please reach out to the relevant scientific/research contact(s) identified in this announcement with any questions about IC-specific research priorities and funding. More SGM- and SGMRO-specific information is available in the NIH Strategic Plan to Advance Research on the Health and Well-being of Sexual and Gender Minorities FY 2021-2025 and on the office’s Research Resources webpage.

For this NOSI, SGMRO encourages research on bioethical issues specific or relevant to SGM individuals and SGM people who are members of other populations that experience health disparities and inequities across the life course. The office also encourages efforts to develop or augment capacity among researchers focused on SGM populations and health that fall within the scope of this NOSI. When appropriate, SGMRO encourages consideration and incorporation of SGM research-relevant concepts (e.g., minority stress, social safety, intersectionality, stigma), research strategies (e.g., community-led or -engaged research, trauma-informed research, strengths-based approaches), and frameworks (e.g., SGM Health Disparities Research Framework, NIMHD Research Framework).

THRO

The Tribal Health Research Office’s mission is to improve Native health, enhance capacity for health research in Native communities, and promote opportunities for the next generation of American Indian and Alaska Native (AI/AN) researchers. In addition, the Tribal Health Research Office (THRO) also looks to develop policies that address ethical research with Tribes and AI/AN populations. THRO is interested in bioethics applications that address topics that are aligned with THRO’s mission and prioritize research areas that will have a high impact on ethical approaches to Native health.

For more information, please see: https://dpcpsi.nih.gov/thro

Scope of Support

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

The proposed studies cannot expand the scope of the parent award. The contribution of the proposed project to the field of bioethics should be made clear in the application.

Future funding for Bioethics research will not be administered as an administrative supplement. NIH will provide details to the extramural research community outlining how the funds will be administered, in the future.

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:

• Application Due Date(s) January 24, 2025, by 5:00 PM local time of applicant organization.
• For funding consideration, applicants must include “NOT-OD-25-015” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
• Application budget cannot exceed a maximum direct cost of $100,000. In addition to the direct cost, applicable F&A (indirect) costs can also be requested.
• Requests may be for one year of support only and cannot exceed the project period of the parent award..
• Note concerning the Award Project Period: Supplement project and budget periods are limited to the remaining active budget period for the existing parent award. To be eligible, the parent award must be active (i.e., not be in an extension period), and the activities proposed in the supplement must be accomplished within the remaining active budget period for the existing parent award.
• The Research Strategy section of the application is limited to 6 pages. The Specific Aims page is not included in this page limit.
• Applications should specify in the Project Summary/Abstract whether the project is specific to bioethics research, capacity building in bioethics, or both.
• All criteria for review in Section V. Application Review Criteria in PA-20-272 will be followed, except that the following criteria will be used instead of the criteria provided for Overall Impact
  • NIH staff will consider the ability of the proposed supplement activities to increase or preserve the parent award’s overall impact within the original scope of award as appropriate:
    • Will the administrative supplement increase or preserve the likelihood for the project to exert an influence on bioethics-related policy or capacity building in the research field(s) involved?
    • Will the administrative supplement provide an evidence base that may inform or support the development of future policy directions?
    • Does the administrative supplement address a bioethical issue that is pressing, recurring, and/or emerging in biomedical and/or health-related behavioral research or capacity building for bioethics?
    • Are the overall strategy, methodology, and analyses proposed in the supplement application well-reasoned and appropriate to accomplish the proposed effort in a one-year period?
• All applications, including those for multi-project activity codes, must be submitted electronically using a single-project application form package.
• Applicant organizations may submit more than one application, provided that each is sufficiently distinct from any other administrative supplement currently under consideration by the awarding NIH Institute or Center. Only one application per parent award may be submitted.
• Applicants are strongly encouraged to notify the program contact at the NIH Institute or Center supporting the parent award that a request has been submitted in response to this FOA in order to facilitate efficient processing of the request.
• List any senior/key personnel who have important roles (e.g., researchers leading the entire aim of the supplement or other official supplement responsibilities) in the supplement as Co-Investigators.
• A separate progress report for these supplements is required under section G.1, Special Reporting Requirements, as part of the Research Performance Progress Report (RPRR) of the parent grant. The progress report for the supplement should describe what was accomplished.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

David Zahavi, PhD
Office of Science Policy, Office of the Director (OSP/OD)
Telephone: 301-827-9702
Email: david.zahavi@nih.gov

Barbara Sina, PhD
Fogarty International Center (FIC)
Telephone: 301-402-9467
Email: sinab@mail.nih.gov

Elaine Collier, MD
National Center for Advancing Translational Science (NCATS)
Telephone: 301-435-0794
Email: colliere@mail.nih.gov

Wendy Weber, ND, PhD, MPH
National Center for Complementary and Integrative Health (NCCIH)
Telephone: 301-402-1272
Email: weberwj@mail.nih.gov

Charlisse Caga-anan, JD
National Cancer Institute (NCI)
Telephone: 240-276-6738
Email: charlisse.caga-anan@nih.gov

Cheri Wiggs, PhD
National Eye Institute (NEI)
Telephone: 301-402-0276
Email: wiggsc@mail.nih.gov

Nicole Lockhart, PhD
National Human Genome Research Institute (NHGRI)
Telephone: 301-385-1622
Email: lockhani@mail.nih.gov

Kathleen N. Fenton, MD, MS
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-6523
Email: kathleen.fenton@nih.gov

Kristina McLinden, PhD
National Institute on Aging (NIA)
Telephone: 301-827-2563
Email: mclindenka@nih.gov

Jane Hettinger, PhD
National Institute on Aging (NIA)
Telephone: 301-529-7446
Email: jane.hettinger@nih.gov

Pamela Wernett, PhD
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-827-5391
Email: wernettpj@mail.nih.gov

Joana Roe, BA
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3213
Email: joana.roe@nih.gov

Emily Carifi, PhD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Telephone: 301-496-0665
Email: emily.carifi@nih.gov

Tuba Fehr, PhD
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-451-7958
Email: tuba.fehr@nih.gov

Tammara Jenkins, MSN, RN, PCNS-BC
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 
Telephone: 301-435-6837
Email: tjenkins@mail.nih.gov

Katia Howlett, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-451-1011
Email: katia.delrahim-howlett@nih.gov

Merav Sabri, PhD
National Institute on Deafness and Other Communication Disorders (NIDCD)
Telephone: 301-827-0908
Email: merav.sabri@nih.gov

Alicia Chou, MS
National Institute of Dental and Craniofacial Research (NIDCR)
Telephone: 301-594-4874
Email: alicia.chou@nih.gov

Aynur Unalp-Arida, MD, MSc, PhD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-8879
Email: aynur.unalp-arida@nih.gov

Kim McAllister, PhD
National Institute of Environmental Health Sciences (NIEHS)
Telephone: 984-287-3287
Email: mcallis2@niehs.nih.gov 

James Churchill, PhD
National Institute of Mental Health (NIMH)
Telephone: 301-443/3621
Email: churchillj@mail.nih.gov

Vanessa J Marshall, PhD
National Institute on Minority Health and Health Disparities (NIMHD)
Phone: 301-827-3788
E-mail: vanessa.marshall@nih.gov

Amy Tsou, MD, MSc
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9135
Email: amy.tsou@nih.gov

Meryl Sufian, PhD
National Library of Medicine (NLM)
Telephone: 301-761-6249
Email: sufianm@mail.nih.gov

Shu Hui Chen, PhD
Office of Data Science Strategy (ODSS)
Telephone: 301-402-5392
Email: shuhui.chen@nih.gov

Shari Feirman, PhD
Office of Research on Women's Health (ORWH)
Telephone: 301-435-6350
Email: shari.feirman@nih.gov

Elizabeth Barr, PhD
Office of Research on Women's Health (ORWH)
Telephone: 301-402-7895
Email: elizabeth.barr@nih.gov

Becky Miller, PhD
Office of Strategic Coordination (OSC)
Telephone: 301-594-9979
Email: becky.miller2@nih.gov

Christopher Barnhart, PhD
Sexual & Gender Minority Research Office (SGMRO)
Telephone: 301-594-8983
Email: christopher.barnhart@nih.gov

Julio Aliberti, PhD
Office of AIDS Research (OAR)
Telephone: 301-651-2614
Email: julio.aliberti@nih.gov

Sheila Caldwell, PhD
Tribal Health Research Office (THRO)
Telephone: 240-338-8464
Email: sheila.caldwell@nih.gov

Peer Review Contact(s)

Not Applicable

Financial/Grants Management Contact(s)

Bruce Butrum
Fogarty International Center (FIC)
Telephone: 301-496-2075
Email: butrumb@mail.nih.gov

Matt Zeback
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-451-8309
Email: matthew.zeback@nih.gov

Debbie Chen
National Center for Complementary and Integrative Health (NCCIH)
Telephone: 301-594-3788
Email: debbie.chen@nih.gov

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov

Karen Robinson Smith
National Eye Institute (NEI)
Telephone: 301-435-8178
Email: kyr@nei.nih.gov

Deanna Ingersoll
National Human Genome Research Institute (NHGRI)
Telephone: 301-435-7858
Email: deanna.ingersoll@nih.gov

Alyse Burton
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-8019
Email: burtonam@mail.nih.gov

Jeff Ball
National Institute on Aging (NIA)
Telephone: 301-403-7736
Email: ballj@nia.nih.gov

Judy Fox
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-443-4704
Email: jfox@mail.nih.gov

Ann Devine
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-669-2988
Email: ann.devine@niaid.nih.gov

Leslie Littlejohn
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Telephone: 301-594-5055
Email: leslie.littlejohn@nih.gov

Tseday Lacy
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-827-7650
Email: tseday.lacy@nih.gov

Margaret Young
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 
Telephone: 301-642-4552
Email: margaret.young@nih.gov

Pamela G. Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-1159
Email: pfleming@nida.nih.gov

Christopher Myers
National Institute on Deafness and Other Communication Disorders (NIDCD)
Telephone: 301-435-0713
Email: myersc@mail.nih.gov

Diana Rutberg
National Institute of Dental and Craniofacial Research (NIDCR)
Telephone: 301-594-4798
Email: rutbergd@mail.nih.gov

Gabriel Hidalgo
National Institute of Dental and Craniofacial Research (NIDCR)
Telephone 301-827-4630
Email: gabriel.hidalgo@nih.gov

Thuthuy Nguyen
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-8825
Email: thuthuynguyen@niddk.nih.gov

Jenny L Greer
National Institute of Environmental Health Sciences (NIEHS)
Telephone: 984-287-3332
Email: jenny.greer@nih.gov

Tamara Kees
National Institute of Mental Health (NIMH)
Telephone: 301-443-8811
Email: tkees@mail.nih.gov

Priscilla Grant
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-8412
Email: pg38h@nih.gov

Chief Grants Management Officer
National Institute of Neurological Disorders and Stroke (NINDS)
Email: ChiefGrantsManagementOfficer@ninds.nih.gov

Andrea Culhane
National Library of Medicine (NLM)
Telephone: 301-402-0069
Email: andrea.culhane@nih.gov

Michael Morse
Office of Strategic Coordination (OSC)
Telephone: 301-435-5446
Email: morsem@od.nih.gov